Calcium deposits form in nearly every tissue in the body, and there is no single method that dissolves all of them. The approach depends entirely on where the deposit sits, how large it is, and what drove it to form. A calcified shoulder tendon, a hardened arterial plaque, a kidney stone, and a lump of calcinosis under the skin are all “calcium deposits,” but they respond to very different treatments. Some can be physically broken apart with shock waves. Others respond to medications that slow or partially reverse mineral buildup. Still others require surgical removal. Understanding which kind you are dealing with is the first step toward the right solution.
Why Calcium Builds Up Where It Should Not
Your body tightly regulates calcium, keeping most of it locked in bones and teeth. When that regulation fails, calcium and phosphate crystals can accumulate in soft tissues, blood vessel walls, tendons, kidneys, and joints. The triggers differ by location. In blood vessels, smooth muscle cells can transform into bone-like cells that actively lay down mineral, a process driven by specific bone-related proteins detected in calcified vessel walls.1PubMed Central. Vascular Calcification: Mechanisms of Vascular Smooth Muscle Cell Calcification In the kidneys, excess calcium in the urine crystallizes into stones. In tendons, chronic micro-injury or metabolic imbalance seeds crystite deposits that grow over time. In autoimmune conditions like scleroderma or dermatomyositis, tissue damage creates a favorable environment for calcium to precipitate under the skin.
Your body also has natural defense systems against unwanted calcification. Proteins like fetuin-A, matrix-Gla protein, and osteopontin patrol the bloodstream and tissues, binding calcium and phosphate before they can crystallize. Research on kidney transplant tissue has shown that these inhibitors cluster specifically around calcified areas, suggesting the body actively tries to contain deposits once they start.2PubMed Central. Fetuin, matrix-Gla protein and osteopontin in calcification of renal allografts When the deposits outpace the inhibitors, clinical problems follow. This balance between pro-calcification forces and anti-calcification defenses is the central biology behind every treatment strategy discussed below.
Shoulder and Tendon Deposits
Calcific tendinitis of the shoulder is one of the most common and treatable forms of calcium deposit. A chalky mass forms inside the rotator cuff tendons, causing pain that can range from a dull ache to excruciating flares when crystals shed into the surrounding tissue. Two well-studied approaches can break these deposits down without open surgery.
Extracorporeal shock wave therapy (ESWT) uses focused sound-wave pulses aimed at the deposit from outside the body. The energy fragments the calcification, and the body gradually clears the debris. In a comparative study, about 58% of patients treated with shock waves alone had no visible calcification on X-ray after two years, and roughly 71% reported good or excellent clinical outcomes.3PubMed Central. Arthroscopy surgery versus shock wave therapy for chronic calcifying tendinitis of the shoulder The researchers concluded shock wave therapy was comparable to arthroscopic surgery and should be preferred given its noninvasive nature.
Results improve when you combine shock waves with ultrasound-guided needling, a technique where a doctor inserts a needle into the deposit under ultrasound guidance to break it up and aspirate some of the calcium paste. One study found the deposit completely disappeared in 60% of patients who received needling plus shock waves, compared with about a third of those treated with shock waves alone.4PubMed. Ultrasound-guided needling combined with shock-wave therapy for the treatment of calcifying tendonitis of the shoulder The combination also reduced the number of patients who eventually needed surgery.
Kidney Stones
Kidney stones are among the few calcium deposits where prevention and dissolution share the same toolkit. Most kidney stones contain calcium oxalate or calcium phosphate, and citrate is the body’s natural countermeasure. Citrate binds calcium in the urine, reducing the amount available to form crystals, and it directly inhibits crystallization.
A Cochrane systematic review found that citrate salts significantly reduced new stone formation and shrank existing stones in people prone to calcium-containing kidney stones.5PubMed Central. Citrate salts for preventing and treating calcium containing kidney stones in adults A separate study of patients with tiny renal microcalculi showed that citrate therapy led to a significant decrease in the number of these micro-stones, while the untreated group saw their numbers grow. The citrate group also experienced fewer pain episodes.6PubMed. Potassium-sodium citrate prevents the development of renal microcalculi into symptomatic stones in calcium stone-forming patients
The picture is not entirely straightforward, though. Potassium citrate raises urine pH and increases phosphate and oxalate excretion, which under certain conditions can actually increase the supersaturation of calcium phosphate, potentially making some stone types worse rather than better.7PubMed Central. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria This complexity is why stone composition matters. If you have primarily calcium oxalate stones, citrate therapy is well-supported. If your stones are predominantly calcium phosphate, the benefit is less certain, and your doctor may need to monitor urine chemistry closely.
Vascular Calcification
Calcium deposits in arteries are harder to reverse than those in tendons or kidneys, and the stakes are higher. Calcified coronary arteries are a strong predictor of heart attack risk. Unlike a kidney stone you can dissolve with citrate or a tendon deposit you can blast with shock waves, arterial calcification is embedded in the vessel wall and intertwined with plaque. No currently approved drug reliably reverses it in humans.
That said, several strategies can slow its progression. Magnesium plays a dual protective role: it both buffers phosphate to reduce mineral crystal formation and directly prevents smooth muscle cells in blood vessel walls from transforming into the bone-like cells that drive the calcification process.8PubMed. Magnesium Counteracts Vascular Calcification: Passive Interference or Active Modulation? Whether magnesium supplements meaningfully slow calcification progression in humans is still an open question, but ensuring adequate intake is a reasonable precaution, especially for people with kidney disease who tend to run low.
Vitamin K2 has attracted significant attention because it activates matrix-Gla protein, one of the body’s key anti-calcification defenses. The activation process also depends on vitamin D3, which stimulates the synthesis of these protective proteins in the first place.9PubMed Central. Effects of vitamins K2 and D3 supplementation in patients with severe coronary artery calcification: a study protocol for a randomised controlled trial The rationale is sound, and clinical trials are underway to test whether combined K2 and D3 supplementation slows coronary calcification in people with established disease. Results from earlier observational studies have been promising enough to justify the trials, but definitive proof is still pending.
The Vitamin D Paradox
Vitamin D deserves its own discussion because it cuts both ways. At adequate levels, vitamin D supports the production of anti-calcification proteins and helps the body regulate calcium properly. But excess vitamin D, whether from mega-dose supplements or clinical toxicity, can drive calcium and phosphate levels so high that mineral crystals deposit in soft tissues. Imbalances in vitamin D metabolism, dietary calcium, and kidney mineral handling are all associated with both bone loss and soft tissue calcification.10PubMed Central. Vitamin D in Vascular Calcification: A Double-Edged Sword?
A study of vitamin D toxicity cases found that about 19% of patients developed nephrocalcinosis, where calcium deposits form in the kidney tissue itself.11PubMed Central. Vitamin D Toxicity: A Prospective Study from a Tertiary Care Centre in Kashmir Valley The takeaway is not to avoid vitamin D, which most people need more of, but to avoid treating calcium deposits by stacking aggressive supplementation without monitoring blood levels. A well-intentioned regimen of high-dose vitamin D plus calcium could theoretically make soft tissue calcification worse.
Sodium Thiosulfate for Severe Cases
Sodium thiosulfate (STS) is a niche but sometimes lifesaving treatment used primarily for calciphylaxis, a dangerous condition seen mainly in people with advanced kidney disease where calcium deposits obstruct small blood vessels in the skin, causing painful, necrotic wounds. STS is thought to work by forming soluble calcium thiosulfate complexes that can be excreted in urine.
In an animal study, rats with chronic kidney disease treated with sodium thiosulfate showed no evidence of aortic calcification, while nearly three-quarters of untreated animals developed it. The treated rats also had significantly lower calcium content in their aortic, heart, and kidney tissue.12PubMed. Sodium thiosulfate prevents vascular calcifications in uremic rats In human case reports, intravenous STS given three times weekly produced rapid improvement in calciphylaxis patients who had not responded to other therapies, with prolonged treatment well tolerated and continued clinical benefit.13PubMed. Successful treatment of calciphylaxis with intravenous sodium thiosulfate STS is not something you can take casually at home; it requires IV administration in a clinical setting and is reserved for serious, medically supervised situations.
Calcinosis in Autoimmune Disease
People with scleroderma, dermatomyositis, and other connective tissue disorders can develop calcinosis cutis, where hard calcium lumps form under the skin, often on fingertips, elbows, and knees. These deposits are painful, prone to infection when they break through the skin, and frustratingly resistant to treatment. No single therapy has been accepted as a standard, and the list of options that have been tried is long: bisphosphonates, diltiazem, minocycline, warfarin, aluminum hydroxide, probenecid, intralesional steroids, intravenous immunoglobulin, surgical excision, and even carbon dioxide laser.14PubMed. Calcinosis cutis: part II. Treatment options
Bisphosphonates are among the more frequently discussed options. They inhibit bone resorption and reduce inflammatory signaling from macrophages, which may help limit the calcification process. Some case reports have shown dramatic improvement, including near-complete resolution of calcified deposits in children with dermatomyositis treated with alendronate. But results are inconsistent. A review of the evidence found that only a minority of patients responded to bisphosphonates, and in some cases, calcinosis actually progressed during treatment.15The Journal of Rheumatology. Management of Calcinosis Cutis in Rheumatic Diseases Mouse models of genetic arterial calcification have been more encouraging, with bisphosphonates significantly reducing mineral deposits in both skin and aortic tissue.16PubMed Central. Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy The gap between encouraging animal data and inconsistent human results is a recurring theme in calcification research.
Joint Crystal Deposits
Calcium pyrophosphate deposition disease (CPPD), sometimes called pseudogout, involves crystals of calcium pyrophosphate settling in joint cartilage. When these crystals shed into the joint fluid, they trigger intense inflammatory flares that mimic gout. Unlike gout, where medications can dissolve uric acid crystals, there is currently no approved drug that dissolves calcium pyrophosphate crystals once deposited.17PubMed Central. Updated Treatment for Calcium Pyrophosphate Deposition Disease: An Insight
Treatment instead focuses on managing the inflammation. Colchicine, NSAIDs, and corticosteroid injections are the mainstays for acute flares, and low-dose colchicine is sometimes used long-term to reduce flare frequency. A systematic review found that management of CPPD is still largely based on expert opinion rather than robust trial data, and much of the treatment rationale is borrowed from gout research.18PubMed. Management of calcium pyrophosphate crystal deposition disease: A systematic review If you have been told you have CPPD, the honest answer is that the crystals themselves are not going away with current therapies. The goal is to control symptoms and check for treatable underlying conditions like hyperparathyroidism or low magnesium that can drive crystal formation.
Salivary Gland Stones
Calcium deposits in the salivary ducts, called sialoliths, block saliva flow and cause painful swelling of the affected gland, usually during meals. These are among the more straightforward calcium deposits to treat mechanically. Sialendoscopy, where a tiny camera is threaded into the duct to visualize and extract the stone, is considered the first-choice approach. But direct extraction without prior fragmentation works only about 15 to 20% of the time, because most stones are too large or wedged too tightly.19PubMed Central. Salivary lithotripsy in the era of sialendoscopy
Shock wave lithotripsy, the same general technology used for kidney stones, has been adapted for salivary stones. Studies have shown it to be painless and effective, with stone clearance or sufficient fragmentation for spontaneous passage achieved in roughly 56 to 59% of patients depending on the gland involved.20PubMed. Efficacy, risks, and limits of extracorporeal shock wave lithotripsy for salivary gland stones The appeal of this approach is that it can preserve the gland, whereas the traditional treatment was surgical removal of the entire gland.
The Immune System’s Role
One reason calcium deposits are so stubborn is that the immune system has a complicated relationship with them. Macrophages, the immune cells responsible for cleaning up debris, can engulf calcium phosphate crystals. But instead of simply clearing them, the crystals often trigger an inflammatory alarm. Engulfed calcium phosphate activates an inflammatory complex inside the macrophage that releases IL-1β, a potent inflammatory signal.21Cardiovascular Research. Two-faced Janus: the dual role of macrophages in atherosclerotic calcification This inflammation can damage surrounding tissue and, paradoxically, promote further calcification. The macrophage response creates a vicious cycle: crystals cause inflammation, inflammation damages tissue, and damaged tissue calcifies more.
This is why anti-inflammatory treatments, colchicine, corticosteroids, and others, are useful even when they cannot dissolve the deposit itself. By breaking the inflammatory loop, they reduce both symptoms and the signals that drive further crystal growth.
The EDTA Chelation Debate
EDTA (ethylene diamine tetraacetic acid) is a chelating agent that binds calcium and has been promoted for decades as an alternative therapy for arterial calcification. The evidence that intravenous EDTA chelation therapy works for this purpose in humans is thin, and the practice carries real risks: it pulls calcium out of the bloodstream indiscriminately, which can lower blood calcium to dangerous levels, increase urinary calcium loss, and potentially harm the kidneys.
Laboratory work, though, shows that EDTA is genuinely effective at removing calcium from mineralized tissue without destroying the tissue’s architecture. Both EDTA and a related chelator called DTPA removed calcium from hydroxyapatite and calcified tissues in lab experiments, while sodium thiosulfate did not perform well in the same chelation tests.22PubMed Central. Efficacy of reversal of aortic calcification by chelating agents The problem is not whether EDTA can dissolve the calcium; it is how to deliver it to the right place without causing systemic side effects.
Researchers have tried to solve this with nanoparticle technology. By loading EDTA into tiny albumin nanoparticles coated with antibodies that bind damaged arterial elastic tissue, they were able to target the chelator directly to calcified vessel walls in rats. The targeted nanoparticles reversed existing heavy mineral deposits in arteries without causing the drops in blood calcium, kidney toxicity, or bone loss seen with plain EDTA injection.23PubMed Central. Reversal of heavy arterial calcification in a rat model of chronic kidney disease using targeted ethylene diamine tetraacetic acid-loaded albumin nanoparticles An earlier proof-of-concept study demonstrated the same principle: targeted EDTA nanoparticles reversed arterial calcification in rats after just four injections over two weeks, with no systemic side effects.24PubMed Central. Targeted chelation therapy with EDTA-loaded albumin nanoparticles regresses arterial calcification without causing systemic side effects This is still strictly preclinical work in animals, but it is among the most promising avenues for eventually reversing established vascular calcification in humans.
Exercise and Coronary Calcium
A common question is whether exercise can reduce coronary artery calcium scores. The short answer is no, but that is not the whole story. A large study of nearly 9,000 adults found that physical activity level had essentially zero effect on the rate of coronary calcium progression, which averaged about 29 to 32% per year regardless of how much people exercised.25JAMA Cardiology. Physical Activity and Progression of Coronary Artery Calcification in Men and Women In fact, highly active middle-aged and older athletes tend to have more coronary calcification than sedentary peers, not less.26PubMed Central. Exercise and Coronary Atherosclerosis: Observations, Explanations, Relevance, and Clinical Management
Before you take that as a reason to cancel your gym membership, the composition of the plaque matters. Athletes tend to have more fully calcified, stable plaques and fewer of the dangerous mixed plaques that are prone to rupture and cause heart attacks. One study found that vigorous exercise was associated with slightly less calcium progression, while very vigorous exercise (think competitive marathon training) was associated with more calcified plaque.27PubMed. Exercise Volume Versus Intensity and the Progression of Coronary Atherosclerosis in Middle-Aged and Older Athletes: Findings From the MARC-2 Study The calcium score may go up with exercise, but that higher number does not translate to higher risk in the same way it does for sedentary people. Exercise remains protective for cardiovascular events overall, even if it does not shrink the deposits themselves.
Emerging Drug Therapies
SNF472, an intravenous form of myo-inositol hexaphosphate (a natural compound found in many foods), represents a new class of calcification inhibitors. It works by binding directly to hydroxyapatite, the mineral crystal that forms the core of most calcium deposits, and blocking further crystal growth. In lab studies, SNF472 bound rapidly and irreversibly to hydroxyapatite and inhibited new crystal formation at low concentrations.28PubMed Central. Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis A randomized phase 2b trial in hemodialysis patients tested whether this mechanism translates clinically, with the drug designed to slow the progression of cardiovascular calcification in this high-risk group.29PubMed. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study
For people with rare genetic calcification disorders, enzyme replacement therapy is under investigation. Pseudoxanthoma elasticum (PXE), caused by mutations that result in low levels of pyrophosphate (the body’s built-in calcification inhibitor), leads to progressive calcification of skin, eyes, and blood vessels. INZ-701, a recombinant form of the enzyme that produces pyrophosphate, prevented ectopic calcification in a mouse model of PXE by restoring the missing inhibitor.30PubMed Central. INZ-701, a recombinant ENPP1 enzyme, prevents ectopic calcification in an Abcc6-/- mouse model of pseudoxanthoma elasticum These approaches are still early-stage, but they point toward a future where the underlying biochemistry of calcification can be corrected rather than just managed symptomatically.
Breast Microcalcifications
Tiny calcium deposits in breast tissue show up on mammograms and understandably cause alarm. But most breast microcalcifications are benign. The clinical question is not usually how to dissolve them but rather what type they are, since the crystal composition carries diagnostic information. Calcium oxalate crystals tend to be associated with benign lesions, while calcium hydroxyapatite crystals are more often found alongside malignant ones. MRI research has demonstrated that these two crystal types produce different imaging signatures, with hydroxyapatite creating artifacts more than twice as large as those from calcium oxalate.31PubMed Central. Using MRI to detect and differentiate calcium oxalate and calcium hydroxyapatite crystals in air-bubble-free phantom Breast microcalcifications are not treated by dissolution. When they raise suspicion, they are biopsied to determine whether the underlying tissue is cancerous, and any treatment targets the disease, not the calcium itself.